Viva5 Corporation Invests Big in Management Team with Appointment of Mark Jaggi as CFO

Company Continues Investment in Seasoned Executive Talent

FOR IMMEDIATE RELEASE
April 2017
Contact: Brian Baer
+1-561-239-2239

SUNRISE, FL (April 12, 2017) — Viva5 Corporation announced today the appointment of Mark Jaggi as Chief Financial Officer. Mr. Jaggi has nearly two decades of financial and leadership experience having served in several C-level financial and leadership roles. Most recently, Mr. Jaggi served from in 2015 through 2016 as Chief Financial Officer at LifeVantage Corp, a public direct seller of supplements. Prior to LifeVantage Mr. Jaggi served from 2012 through 2015 EVP and Chief Financial Officer for Twinlab Corp. While at Twinlab, Mr. Jaggi, was responsible for managing significant financial and operating improvements along with several financial debt and equity transactions involving buying and selling businesses and brands in addition to taking the company public.

“I am delighted to bring Mark Jaggi on board as CFO. As part of our commitment to growth, we are enhancing our management team,” said Viva 5 President, Brian Baer. “Attracting someone of Mark’s caliber is a testament to the significant value we are creating at Viva 5. Mark has substantial experience in all aspects of the supplement business and he brings a powerful accounting and analytical financial perspective, including experience with change and high growth. He will be instrumental in helping our company stay ahead of the change that our growth brings, and in refining and implementing our growth strategy by continuing to expand our unique product and service offerings.”

“It is truly an exciting time to join the Viva 5 team and have the opportunity to better leverage the company’s strong positioning with the unique products at Viva5,” said Jaggi. “I look forward to continuing to build the company’s infrastructure and aggressively supporting and developing the many growth opportunities in the pipeline.”

Prior to joining Twinlab, Mr. Jaggi’s experience includes serving as Chief Financial Officer for a private consumer products manufacturer and also an online & brick and mortar supplement retailer. He also served as director of finance at a mid-size private equity backed consumer products manufacturing company. Mr. Jaggi began his career with Ford Motor Company in finance in various areas of the company including mergers and acquisitions, marketing and sales, dealer operations, then to product development and manufacturing. Mr. Jaggi holds a bachelors degree in finance from the David Eccles school of business at the University of Utah and received his MBA from the Fuqua school of business at Duke university.

###

FOR FURTHER INFORMATION ABOUT VIVA 5 CORPORATION OR ROBINSON PHARMA, PLEASE CONTACT:

Brian Baer
President
Viva 5 Corporation
Ph: +1-561-239-2239

ABOUT VIVA 5 CORPORATION
Viva 5 Corporation is a US and International leader in sourcing, product development, manufacturing, regulatory & marketing support for a variety of channels in the nutrition health & beauty, and pharmaceutical industries. Viva 5 specialties include the development of innovative, proprietary, and efficacious products that create incremental revenue opportunities for its distribution and retail partners worldwide. For more information, please visit www.viva5corp.com or call 1-561-239-2239.

Viva 5 Corporation Demonstrates Long-term Stability of Probiotic Gummies

FOR IMMEDIATE RELEASE
February 2016
Contact: Brian Baer
+1-561-239-2239

Innovative Manufacturing Technology used to Stabilize Probiotics in Gummies

SUNRISE, FL (February 8, 2016) –  􀍴􀍲Viva 5 Corporation, a US-based probiotic specialist, announces they have demonstrated 18 months of real-time stability with their Bacillus coagulans probiotic gummies. Viva 5 has developed a proprietary manufacturing process which allows for the addition of the probiotic into the gummy matrix, rather than as a component of the sugar coating, allowing high recovery after manufacture and robust stability over an extended period of 18 months.

Accelerated testing further indicates probiotic stability over a 24-month period, making Viva 5 Corporation the only known manufacturer worldwide to offer an active probiotic gummy with such compelling shelf life. This highly stable probiotic can tolerate higher temperatures during manufacturing than traditional lactic acid bacteria, thereby conferring superior shelf-life stability in gummies and other finished products containing this strain.

“Probiotic stability is a big challenge in the industry and we are very pleased to see that our accelerated stability trend has been substantiated by extended real time shelf life studies,” says Brian Baer, President of Viva 5. “With the growth of probiotic sales in dietary supplements, as well as gummy delivery forms, we expect to see continued high demand for our shelf stable probiotic gummies worldwide.”

B. coagulans strain has been shown to support a healthy immune system as well as maintain healthy digestion. Due to its superior stability and durability, as well as demonstrated clinical efficacy, this strain lends itself to a wide variety of formulation opportunities. Viva 5 Corp has also offers this probiotic strain in a softgel delivery form, as well as soft chews and panned chews.

Baer continues, “Expanding delivery options for probiotics offers access to a wider group of consumers including the elderly and children, who may struggle to take products in a capsule form.”

In addition to probiotic gummies, Viva 5 has recently added Immunobiotic Gummies to their portfolio after partnering with Mitsubishi International Food Ingredients, a specialty ingredients company, to develop and help commercialize the proprietary “ImmunoLP-20™” ingredient in gummy delivery forms.

Baer adds, “We believe the ImmunoLP-20™ strain is an ideal candidate for such a product in the marketplace due to its scientific support and superior stability over traditional commercial probiotic products.”

Originally isolated from a fermented traditional Asian food, ImmunoLP-20™ is a specially-derived Lactobacillus plantarum L-137 strain, super potentiated for its balanced immune benefits with a 5 Year Shelf Life. It’s also referred to as an “Immunobiotic” for its clinically studied benefit to positively influence balanced immune function and improve quality of life.

While probiotics have been one of the most successful dietary supplement categories in North America over the past few years, growth is expected to continue in the foreseeable future as more people become aware of the digestive and immune benefits of probiotics.

###

FOR FURTHER INFORMATION ABOUT VIVA 5 CORPORATION OR ROBINSON PHARMA, PLEASE CONTACT:

Brian Baer
President
Viva 5 Corporation
Ph: +1-561-239-2239

ABOUT VIVA 5 CORPORATION
Viva 5 Corporation is a US and International leader in sourcing, product development, manufacturing, regulatory & marketing support for a variety of channels in the nutrition health & beauty, and pharmaceutical industries. Viva 5 specialties include the development of innovative, proprietary, and efficacious products that create incremental revenue opportunities for its distribution and retail partners worldwide. For more information, please visit www.viva5corp.com or call 1-561-239-2239.

Viva 5 Corporation and Robinson Pharma Sign Agreement to Partner on Probiotic Softgels

FOR IMMEDIATE RELEASE
September 2015
Contact: Brian Baer
+1-561-239-2239

SUNRISE, FL (Sept 22, 2015) — Viva 5 Corporation, a US-based probiotic specialist, has formed a partnership with Robinson Pharma, a leading softgel manufacturing company, to help commercialize probiotic softgels worldwide. The five-year supply agreement allows Viva 5 to help commercialize a full line of probiotic softgels using [Read more…]

Viva 5 Corporation and Mitsubishi Ingredients Partner on Immunobiotic Gummies

FOR IMMEDIATE RELEASE
September 2015
Contact: Brian Baer
+1-561-239-2239

SUNRISE, FL SUNRISE, FL (May 19, 2015) — Viva 5 Corporation, a US-based probiotic specialist, is joining forces with Mitsubishi International Food Ingredients, a specialty ingredients company, to develop and help commercialize the proprietary “Immuno-LP20TM” ingredient in Gummy delivery forms.

Originally isolated from a fermented traditional Asian food, [Read more…]

Probi and Viva 5 Corporation form Probiotic Business Development Alliance in North America

FOR IMMEDIATE RELEASE
December 2012
Contact: Tony Corey
+1-954-331-8153

SUNRISE, FL (December 11, 2012)— Viva 5 Corporation, a US-based probiotic specialist, has signed a business development agreement with Probi, a leading provider of world-leading probiotics, to license and help commercialize the consumer healthcare market for Probi Digestis® and Probi Defendum® in North America.

Viva 5 will work with Probi to further strengthen its commercial position, as well as [Read more…]